Jonathan Graham

Tektronix, Inc. provides test, measurement and monitoring solutions. It provides services for the communications, computer, semiconductor industries, as well as for the military, aerospace, consumer electronics and education sectors. The firm also assists its clients in designing, building, deploying and managing global communications networks, computing and advanced technologies. The company was founded by Melvin Jack Murdock, Glenn Leland, Miles Tippery and Charles Howard Vollum in 1946 and is headquartered in Beaverton, OR.

Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA.

Beckman Coulter, Inc. manufactures and distributes biomedical testing instrument systems and general biomedical research products. It develops and markets products that simplify, automate and innovate complex biomedical testing. The firm’s systems operate in both diagnostics and life sciences laboratories on seven continents. Its products improve the productivity of medical professionals and scientists, supplying critical information for improving patient health and delivering trusted solutions for research and discovery. The company was founded in 1935 by Arnold O. Beckman and is headquartered in Brea, CA.

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

Williams & Connolly LLP provides legal services, focusing on litigation areas such as corporate, tax, and employment law. Its practice areas includes administrative law, antitrust, appellate, arbitration, business transactions and tax, criminal defense, employment and labor laws, federal programs, and national defense. The company was founded Edward Bennett Williams in 1967, and is headquartered in Washington, DC.